Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Familial HLH is a success story in modern medicine. Initially a disease that was largely unknown and fatal, it is now understood on a molecular level and is curable. Moreover, HLH is an archetype ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and ...

A 29-year-old man with well-controlled HIV infection presented with a 1-week history of a painful, whitish discoloration on his tongue. Smooth, pink, guttate macules were present on the tongue ...

A total of 867 patients underwent randomization: 291 were assigned to receive acalabrutinib–venetoclax, 286 acalabrutinib–venetoclax–obinutuzumab, and 290 chemoimmunotherapy (of whom 143 ...

To the Editor: The phase 3 NIAGARA trial reported by Powles et al. (Nov. 14 issue), 1 which evaluated perioperative durvalumab with neoadjuvant chemotherapy in muscle-invasive bladder cancer ...

Supported by the Advanced Research Projects Agency for Health (agreement number, 140D042490001); a grant (R01HL141408) from the National Heart, Lung, and Blood Institute; a grant (R01FD007632 ...